Huntington Reproductive Center, Encino, California 91436, USA.
Fertil Steril. 2012 Jun;97(6):1351-8. doi: 10.1016/j.fertnstert.2012.02.038. Epub 2012 Mar 28.
To compare live birth rates after fresh embryo transfer (ET) and cumulative ongoing pregnancy rates after fresh ET and frozen-thawed (ET) between continents and overall after one treatment cycle with corifollitropin alfa or recombinant FSH.
Double-blind, multicenter, randomized controlled trial.
Fourteen centers in North America (NA); 20 in Europe (EU).
PATIENT(S): 804 NA patients and 702 EU patients.
INTERVENTION(S): Patients >60 kg received a single dose of corifollitropin alfa or daily rFSH for the first 7 days of controlled ovarian stimulation.
MAIN OUTCOME MEASURE(S): Live birth rates.
RESULT(S): Within each continent no differences were noted between the two treatment groups; however, between continents, the cumulative ongoing pregnancy rate and live birth rate were considerably higher in NA than in EU. The live birth rate in NA was 39.2% in both treatment groups compared with 31.5% and 28.8% in EU after corifollitropin alfa and rFSH treatment, respectively. Considering the number of embryos transferred, the live birth rate per ET was still higher in NA than in EU (42.7% v.s 36.8% with corifollitropin alfa and 41.6% vs. 30.9% with rFSH). Overall live birth rates after fresh ET were 35.6% and 34.4% (estimated difference 1.1% [95% confidence interval -3.7-5.8]), and the estimated cumulative live birth rates were 43.4% and 41.3% with corifollitropin alfa and rFSH, respectively.
CONCLUSION(S): Live birth rates and cumulative pregnancy rates were higher in NA than in EU after treatment with either corifollitropin alfa or daily rFSH; both treatment protocols provided equal success rates. CLINICALTRIALS.GOV IDENTIFIERS: NCT00703014 and NCT00702273.
比较在新鲜胚胎移植（ET）后活产率和新鲜 ET 与冻融 ET 后累积持续妊娠率，并比较使用戈那瑞林或重组 FSH 进行一次治疗周期后的全球活产率。
双盲、多中心、随机对照试验。
北美 14 个中心（NA）；欧洲 20 个中心（EU）。
804 名 NA 患者和 702 名 EU 患者。
体重 >60kg 的患者接受戈那瑞林或重组 FSH 单次剂量，用于控制性卵巢刺激的前 7 天。
活产率。
在每个大陆内，两组治疗之间没有差异；然而，在大陆之间，NA 的累积持续妊娠率和活产率明显高于 EU。在戈那瑞林和重组 FSH 治疗组中，NA 的活产率分别为 39.2%和 31.5%、28.8%。考虑到移植胚胎的数量，NA 的每个 ET 活产率仍高于 EU（戈那瑞林组为 42.7%，重组 FSH 组为 41.6%）。新鲜 ET 后活产率分别为 35.6%和 34.4%（估计差值为 1.1%[-3.7 至 5.8]），戈那瑞林和重组 FSH 的累积活产率分别为 43.4%和 41.3%。
在使用戈那瑞林或重组 FSH 治疗后，NA 的活产率和累积妊娠率高于 EU；两种治疗方案均具有相同的成功率。
NCT00703014 和 NCT00702273。
